Compare Biogen Inc (BIIB) vs GE Aerospace (GE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs GE Aerospace — how do they compare? Biogen Inc trades at $211.32 (market cap $30.86B), while GE Aerospace trades at $365.58 (market cap $379.05B). The key difference: GE Aerospace is far larger — about 12.3× Biogen Inc's market cap, and GE Aerospace pays a 0.51% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | GE | |
|---|---|---|
Market Cap | $30.86B | $379.05B |
Sector | Health | Industrials |
52-Week High | $216.63 | $381.22 |
52-Week Low | $132.22 | $265.93 |
Enterprise Value | $37.93B | $388.86B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
GE Aerospace trades at $368.06, up 0.37% with strong technical momentum and bullish analyst sentiment. The company demonstrates robust fundamentals with Q2 2026 EPS of $2.02 beating expectations and revenue growth accelerating to $45.86B in 2025. Recent defense contract wins and commercial engine demand fuel optimism, though elevated valuation metrics warrant caution.
Outlook remains positive with 68.6% analyst buy ratings and $414.11 consensus target suggesting 12.5% upside. Key risks include high debt levels and rich valuations, but strong order backlog and defense contracts provide growth catalysts. Earnings momentum and institutional support position GE for continued outperformance in aerospace sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →
